RETA Stock Skyrockets As FDA Approves Reata Phama’s Neurological Drug | Investor’s Business Daily – Investor’s Business Daily

1. RETA Stock Skyrockets As FDA Approves Reata Phama’s Neurological Drug | Investor’s Business Daily Investor’s Business Daily
2. FDA Widens Path for Rare-Disease Treatments With New Approval The Wall Street Journal
3. Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia Business Wire
4. FDA approves Reata’s treatment for rare neurological disease STAT
5. Reata Pharmaceuticals Friedreich’s ataxia drug omaveloxolone wins FDA approval (RETA) Seeking Alpha
6. View Full Coverage on Google News

Read original article here